Skip to main
SLN

Silence Therapeutics (SLN) Stock Forecast & Price Target

Silence Therapeutics (SLN) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Silence Therapeutics is well-positioned in the biotech industry with promising therapies in multiple therapeutic areas. Its Divesiran therapy has a strong potential to address unmet needs in PV, with a high chance of success based on its mechanism of action and past clinical de-risking. With a favorable risk-benefit profile and a diverse pipeline, Silence Therapeutics is a compelling investment opportunity for those seeking exposure to the rapidly growing siRNA market.

Bears say

Silence Therapeutics is currently focused on developing products in three therapeutic areas, but there is not enough data to support the potential for success in any of these areas. The company's NPV analysis is based on conservative assumptions and partnerships, leaving much room for error. Additionally, its market cap remains low despite positive validation and Phase 1 data, indicating a lack of confidence in its potential success.

Silence Therapeutics (SLN) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Silence Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Silence Therapeutics (SLN) Forecast

Analysts have given Silence Therapeutics (SLN) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Silence Therapeutics (SLN) has a Strong Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Silence Therapeutics (SLN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.